Metamizil

Metamizil

Clinical data
Drug class	muscarinic antagonist (anticholinergic drug); sedative and hypnotic
ATC code	None
Identifiers
IUPAC name 1-(diethylamino)propan-2-yl 2-hydroxy-2,2-diphenylacetate
CAS Number	57-36-3
PubChem CID	65527
CompTox Dashboard (EPA)	DTXSID50972485
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES CCN(CC)CC(C)OC(=O)C(C1=CC=CC=C1)(C2=CC=CC=C2)O
InChI InChI=1S/C21H27NO3/c1-4-22(5-2)16-17(3)25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17,24H,4-5,16H2,1-3H3 Key:QTLYTFJMPQZTRQ-UHFFFAOYSA-N

Metamizil is a central anticholinergic drug and a tranquilliser with powerful sedative and hypnotic effects; it was studied during the Soviet era by Soviet scientists alongside amizil.

Pharmacology

Metamizil acts as a muscarinic antagonist and, at a dose of 2 mg/kg, blocks the symptoms of parkinsonism (hypokinesia, rigidity and tremor). Metamizil was used as premedication, and is a strong sedative.

The median lethal dose following intraperitoneal administration was 118 mg/kg (mouse).

Uses

It has been suggested that it be used in the treatment of neuroses in dogs and humans. Sometimes as premedication (as a tranquilliser). As well as in the treatment of vascular parkinsonism and cerebral palsy.

Side effects

The reported side effects included dizziness and a dry mouth.